Ascendiant Capital Markets Raises Vivos Therapeutics (NASDAQ:VVOS) Price Target to $3.10

Vivos Therapeutics (NASDAQ:VVOS) had its price target boosted by research analysts at Ascendiant Capital Markets from $3.00 to $3.10 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price points to a potential upside of 382.04% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Monday, April 20th. HC Wainwright cut their price target on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vivos Therapeutics has a consensus rating of “Hold” and a consensus target price of $2.80.

Vivos Therapeutics Stock Performance

Shares of NASDAQ VVOS opened at $0.64 on Thursday. The company has a quick ratio of 0.27, a current ratio of 0.27 and a debt-to-equity ratio of 3.31. The firm’s 50-day moving average price is $0.91 and its two-hundred day moving average price is $1.51. Vivos Therapeutics has a 52-week low of $0.55 and a 52-week high of $7.95. The stock has a market capitalization of $8.94 million, a P/E ratio of -0.30 and a beta of 6.10.

Vivos Therapeutics (NASDAQ:VVOS) last issued its earnings results on Wednesday, May 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%.The business had revenue of $5.14 million during the quarter, compared to the consensus estimate of $4.35 million. As a group, sell-side analysts forecast that Vivos Therapeutics will post -1.39 earnings per share for the current year.

Insider Buying and Selling at Vivos Therapeutics

In other Vivos Therapeutics news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the business’s stock in a transaction dated Tuesday, March 31st. The shares were bought at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the acquisition, the insider owned 1,353,625 shares in the company, valued at approximately $1,813,857.50. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Vivos Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Acorn Wealth Advisors LLC acquired a new position in shares of Vivos Therapeutics during the fourth quarter valued at approximately $30,000. XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics during the second quarter valued at approximately $65,000. Sequoia Financial Advisors LLC acquired a new position in shares of Vivos Therapeutics during the first quarter valued at approximately $28,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics during the second quarter valued at approximately $220,000. Finally, DRW Securities LLC increased its stake in shares of Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after acquiring an additional 74,441 shares during the period. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.